This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Pre-exposure Prophylaxis Found to be as Safe as Aspirin

Comments
Print

Pre-exposure prophylaxis (PrEP) is the first medicine that the Food and Drug Administration (FDA) has approved to be shown effective to prevent infection with HIV. Nearly 50,000 new cases of HIV occur in the United States every year. Many doctors might be worried about prescribing PrEP for safety reasons.

Researchers Noah Kojima, a second-year medical student at the David Geffen School of Medicine at UCLA, and Dr. Jeffrey Klausner, professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA and of public health at the UCLA Fielding School of Public Health, reviewed major studies of both PrEP for HIV prevention and aspirin for heart attack prevention. They found that both had similar low rates of serious side effects. Aspirin users rarely had serious bleeding or death and PrEP users rarely had serious kidney or bone damage.

By showing that PrEP might be as safe as aspirin doctors should feel more comfortable prescribing it, and patients should feel more comfortable using it. PrEP works very well to prevent HIV when taken every day. The data also could support efforts to make PrEP available without a prescription as an over-the-counter medication like the Plan B morning-after contraceptive pill or birth control in some places.

Their research, funded by the UCLA Center for AIDS Research-UCLA AIDS Institute, was published in Open Forum Infectious Diseases.

Source: University of California, Los Angeles Health Sciences

Comments
comments powered by Disqus